10:31 ETPost-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsightprnewswire·Jul 7 at 09:32 AMAMLX-4.72%4547
Kissei Pharmaceutical's (TSE:4547) Solid Earnings May Rest On Weak FoundationsSimplywall·May 18 at 05:05 PM4547
Dow Jones Top Company Headlines at 5 PM ET: SpaceX Is Aiming to Go Public on June 12 in What Stands to Be Biggest IPO Ever | Anthropic ...MorningStar·May 15 at 04:30 PMBRK.A-9.00%SBUX+0.35%
Kissei Pharmaceutical (TSE:4547) One Off Gain Lifts Margin And Tests Bullish Earnings NarrativeSimplywall·May 12 at 05:11 AM4547
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit RecoveryTip Ranks·May 11 at 03:04 AM4547
Jefferies Sticks to Their Buy Rating for Kissei Pharmaceutical Co (KSPHF)Tip Ranks·May 3 at 07:26 AM4547
Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment PortfolioTip Ranks·Mar 18 at 08:22 PM4547
